GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction
Joshua Reitz, Daniel B Rosoff, Pal Pacher, Falk W Lohoff · 2026
Read GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction by Joshua Reitz, Daniel B Rosoff, Pal Pacher, Falk W Lohoff (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13572310.txt.
Description
Joshua Reitz and colleagues review, in a 2026 article, whether diabetes and weight-loss drugs that mimic the gut hormone GLP-1, including newer dual-action versions, could also treat alcohol use disorder. Heavy drinking and metabolic dysfunction overlap heavily and together drive liver disease, making a shared treatment attractive.
The drugs are already approved for diabetes and obesity and are under study for fatty liver disease. Evidence so far suggests they may cut alcohol intake while steadying metabolism, with the dual approach possibly filling a gap for people carrying both problems. The authors map ongoing trials and open questions, framing addiction care around metabolic circuits rather than willpower alone.
Catalog record
| CREATOR | Joshua Reitz, Daniel B Rosoff, Pal Pacher, Falk W Lohoff |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48233 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |